The Role of the Imaging FAPI PET/CT in Exploring the Microenvironment of Colorectal Cancer Liver Metastases

Condition(s) studied

Investigational drug(s) / intervention(s)

FAPI PET/CT: Patient will undergo FAPI PET/CT Prior to surgery

Study summary

FAPI PET/CT molecular imaging represents a cutting-edge advancement in oncological imaging, particularly for the preoperative assessment of colorectal liver metastases (CRLM). Fibroblast activation protein inhibitors (FAPIs), which are the focus of this imaging modality, selectively target cancer-associated fibroblasts, a critical component of the tumor microenvironment. FAPI PET/CT could be useful in the detection of HGP (Histological Growth Pattern) and in the changes during neoadjuvant chemotherapy prior to surgery

Eligibility

Primary outcome measure(s)

• The quantification of IHC staining for FAP-expressing CAFs measured in patient-derived tissue specimens — from the enrollement to the surgery date, approximately 3 to 4 weeks
• The quantification of FAP expression on FAPI PET/CT (SUVmax, SUVmean, MTV [metabolically active tumor volume], FAPI-TV [FAPI positive tumour load]) — From enrollment to surgery date, approximately 3 to 4 weeks
• correlation between the value of FAPI PET/CT and the percent encapsulated, and the HGP scores (desmoplastic, replacement, pushing) of the liver metastasis — from the enrollment to the anapathological analysis date,approximately 4 to 5 weeks

Trial sites (1)

More Jules Bordet Institute trials in Belgium